【摘 要】
：
Fasiglifam (TAK-875), a selective G-protein-coupled receptor 40 agonist, was developed for the treatment of type 2 diabetes mellitus.However, its clinical d
【机 构】
：
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
【出 处】
：
2015年第一届药代动力学朝阳论坛
论文部分内容阅读
Fasiglifam (TAK-875), a selective G-protein-coupled receptor 40 agonist, was developed for the treatment of type 2 diabetes mellitus.However, its clinical development was terminated in phase Ⅲ clinical trials due to liver safety concerns.Our preliminary study indicated intravenous administration of 100 mg/kg of TAK-875 increased the serum total bile acid concentration by 2.2 times in rats.In the present study, we examined the inhibitory effects of TAK-875 on hepatobiliary transporters to determine the mechanisms underlying its hepatotoxicity.TAK-875 decreased the biliary excretion index and the in vitro biliary clearance of d8-taurocholic acid (d8-TCA) as a probe for bile acids transport in sandwich cultured rat hepatocytes, suggesting that TAK-875 impaired biliary excretion of bile acids, possibly by inhibiting bile salt export pump (Bsep).TAK-875 inhibited the efflux transporter muhidrug resistance-associated protein 2 (Mrp2) in rat hepatocytes using 5 (and 6)-carboxy-2', 7'-dichlorofluorescein as a substrate.
其他文献
When evaluating clinical drug-drug interactions (DDI), revealing whether and how the role of the metabolic status in the entire drug disposition in vivo aff
The circulating microRNAs (miRNAs) own many characteristics of biomarkers and can be released from platelet.We hypothesize plasma miRNA level can reflect th
Our study aimed at the investigation of in vivo anticancer effect of the combination use of dexamethasone (DEX) and gemcitabine (GM) as well as the developm
Drug metabolism has become an integral part of drug discovery and development from the earliest stage, and this change may have been driven by the evolution
Diosbulbin B (DIOB) is the most abundant component of Dioscorea bulbifera L.(DB), a traditional Chinese medicine herb.DIOB and DB extracts have been reporte
The recognition of the gut microbiota-host metabolic axis and its implications in human metabolic disease has highlighted the contribution of the gut microb
LAT1 overexpressed on membrane of various tumor cells, are potential targets for tumor-targeting therapy.This study aimed to develop a LAT1-mediated drug de
CPRC1 is a novel investigated proton pump inhibitor, which shows dramaticsuccess in the management of acid-related disorders.Now this drug is being develope
Prediction of human PK at the preclinical stage can aid: ① human efficacious dose prediction, ②) human safety risk assessment based on detailed pharmacoki
Trastuzumab Emtansine(T-DM1, KadcylaTM, Genentech Inc.) is an antibody-drug conjugate(ADC) that received US FDA approval in 2013 for the treatment of human